103. Nat Commun. 2018 Mar 16;9(1):1107. doi: 10.1038/s41467-018-03441-3.A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.Ladds MJGW(1)(2), van Leeuwen IMM(1), Drummond CJ(1), Chu S(3), Healy AR(4),Popova G(1), Pastor Fernández A(1), Mollick T(1)(2), Darekar S(1)(2), SedimbiSK(1)(2), Nekulova M(1)(5), Sachweh MCC(1), Campbell J(6), Higgins M(6), TuckC(1), Popa M(7), Safont MM(7), Gelebart P(7), Fandalyuk Z(7), Thompson AM(8),Svensson R(9), Gustavsson AL(10), Johansson L(10), Färnegårdh K(11), Yngve U(12),Saleh A(12), Haraldsson M(11), D'Hollander ACA(4), Franco M(1), Zhao Y(13),Håkansson M(14), Walse B(14), Larsson K(1), Peat EM(15), Pelechano V(2), LunecJ(13), Vojtesek B(5), Carmena M(15), Earnshaw WC(15), McCarthy AR(1), WestwoodNJ(4), Arsenian-Henriksson M(1), Lane DP(1)(2), Bhatia R(3), McCormack E(7)(16), Laín S(17)(18).Author information: (1)Department of Microbiology, Tumor and Cell Biology (MTC), KarolinskaInstitutet, SE-171 77, Stockholm, Sweden.(2)SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC),Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden.(3)Division of Hematology and Oncology, Comprehensive Cancer Center, 1720 2ndAvenue South, NP2540, Birmingham, AL, 35294-3300, USA.(4)School of Chemistry and Biomedical Sciences Research Complex, University ofSt. Andrews and EaStCHEM, St. Andrews, Fife, Scotland, KY16 9ST, UK.(5)RECAMO, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 65653, Brno, CzechRepublic.(6)Centre for Oncology and Molecular Medicine, University of Dundee, NinewellsHospital and Medical School, Dundee, Tayside, DD1 9SY, UK.(7)Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science,Hematology Section, University of Bergen, 5021, Bergen, Norway.(8)Department of Breast Surgical Oncology, MD Anderson Cancer Center, HolcombeBoulevard, Houston, 77030, USA.(9)Department of Pharmacy, Uppsala University Drug Optimization andPharmaceutical Profiling Platform (UDOPP), Department of Pharmacy, UppsalaUniversity, SE-752 37, Uppsala, Sweden.(10)Chemical Biology Consortium Sweden, Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistryand Biophysics, Karolinska Institutet, SE-171 21, Stockholm, Sweden.(11)Drug Discovery and Development Platform, Science for Life Laboratory,Tomtebodavägen 23, SE-171 21, Solna, Sweden.(12)Department of Medicinal Chemistry, Science for Life Laboratories, UppsalaUniversity, SE-751 23, Uppsala, Sweden.(13)Newcastle Cancer Centre, Northern Institute for Cancer Research, NewcastleUniversity, Newcastle, NE1 7RU, UK.(14)SARomics Biostructures, Medicon Village, SE-223 81, Lund, Sweden.(15)The Wellcome Trust Centre for Cell Biology, Institute of Cell Biology,University of Edinburgh, Edinburgh, EH9 3JR, UK.(16)Department of Medicine, Haematology Section, Haukeland University Hospital,Bergen, Norway.(17)Department of Microbiology, Tumor and Cell Biology (MTC), KarolinskaInstitutet, SE-171 77, Stockholm, Sweden. sonia.lain@ki.se.(18)SciLifeLab, Department of Microbiology, Tumor and Cell Biology (MTC),Karolinska Institutet, Tomtebodavägen 23, SE-171 21, Stockholm, Sweden.sonia.lain@ki.se.Erratum in    Nat Commun. 2018 May 22;9(1):2071.The development of non-genotoxic therapies that activate wild-type p53 in tumors is of great interest since the discovery of p53 as a tumor suppressor. Here wereport the identification of over 100 small-molecules activating p53 in cells. Weelucidate the mechanism of action of a chiral tetrahydroindazole (HZ00), andthrough target deconvolution, we deduce that its active enantiomer (R)-HZ00,inhibits dihydroorotate dehydrogenase (DHODH). The chiral specificity of HZ05, a more potent analog, is revealed by the crystal structure of the (R)-HZ05/DHODHcomplex. Twelve other DHODH inhibitor chemotypes are detailed among the p53activators, which identifies DHODH as a frequent target for structurally diverse compounds. We observe that HZ compounds accumulate cancer cells in S-phase,increase p53 synthesis, and synergize with an inhibitor of p53 degradation toreduce tumor growth in vivo. We, therefore, propose a strategy to promote cancer cell killing by p53 instead of its reversible cell cycle arresting effect.DOI: 10.1038/s41467-018-03441-3 PMCID: PMC5856786PMID: 29549331  [Indexed for MEDLINE]